NCT05636514 2026-03-18
CELESTIAL-MDS
Clinical Hub for Interventional Research (CHOIR)
Phase 1 Recruiting
Clinical Trials
17 trialsNCT07135466 2026-01-16
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Sheba Medical Center
Phase 1/2 Recruiting
NCT06782971 2025-12-08
COSMOS-Avatar
Clinical Hub for Interventional Research (CHOIR)
Recruiting
NCT07258043 2025-12-02
EPOCH
Hospital General de Mexico
Recruiting
NCT06409767 2025-09-24
ALHERT
University Hospital, Angers
Phase NA Recruiting
NCT07014865 2025-08-29
MMYLIFE
Azienda USL Reggio Emilia - IRCCS
Recruiting
NCT07061145 2025-08-06
ED2024
Azienda USL Reggio Emilia - IRCCS
Recruiting
NCT06795815 2025-06-12
OHGW-ACP
Azienda USL Reggio Emilia - IRCCS
Phase NA Recruiting
NCT06793410 2025-06-05
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
Phase 2 Recruiting
NCT04691284 2025-05-29
SCTMICROBIOM
National Cancer Institute, Slovakia
Phase NA Recruiting
NCT06961669 2025-05-29
ECAR01
Anhui Provincial Hospital
Phase NA Recruiting
NCT06299462 2025-02-25
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
Phase 1/2 Recruiting
NCT06758713 2025-01-06
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
The Third Affiliated Hospital of Southern Medical University
Phase 1 Recruiting
NCT02416388 2024-08-07
BIG-1
University Hospital, Angers
Phase 2/3 Recruiting
NCT05536154 2024-03-19
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Recruiting
NCT05648019 2023-03-09
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital
Phase 2 Recruiting
NCT05528887 2022-09-06
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase 1 Recruiting